<DOC>
	<DOCNO>NCT00003175</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness fluorouracil give continuous infusion treat patient recurrent metastatic bladder cancer .</brief_summary>
	<brief_title>Fluorouracil Treating Patients With Recurrent Metastatic Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate toxic effect continuous fluorouracil patient recurrent locally advanced metastatic transitional cell urinary tract carcinoma . II . Determine feasibility treatment patient population . OUTLINE : Patients receive continuous intravenous fluorouracil Baxter Infusor 24 week . Patients evaluate complete partial response 8 , 16 , 24 week start intravenous fluorouracil . Patients experience disease progression unacceptable toxic effect remove study . Patients follow monthly 6 month post treatment . PROJECTED ACCRUAL : A maximum 45 patient accrue .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent locally advance metastatic transitional cell urinary tract carcinoma previously untreated systemic chemotherapy Pelvic relapse radiotherapy surgery No relapse solely within previously irradiate field Nodal metastatic disease Lesions within abdomen pelvis must assess use CT scan At least one site disease must previously unirradiated assessable response Bone metastases use indicator lesion Measurable disease PATIENT CHARACTERISTICS : Age : Not specify Performance Status : Not specify Life Expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Glomerular filtration rate least 50 mL/min Creatinine clearance least 25 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>